Investor Relations - Curis

Feb 2, 2021

Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

- Phase 2 study sponsored by investigators at Universität Leipzig in Germany -

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the initiation of a Phase 2...
Jan 14, 2021

Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
Jan 8, 2021

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent...
Jan 5, 2021

Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...

Show per page